<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DILAUDID- hydromorphone hydrochloride tablet </strong><br>Cardinal Health<br></p></div>
<h1>Dilaudid (hydromorphone hydrochloride) Oral Liquid<br>Dilaudid (hydromorphone hydrochloride) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_3ac3dae9-b522-44e9-9ce9-968cf8077fc2"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Bold">WARNING: DILAUDID ORAL LIQUID AND DILAUDID TABLETS CONTAIN</span></span><span class="Bold">HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED</span><span class="Bold">OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS, INCLUDING </span><span class="Bold">MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE,</span><span class="Bold">HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF</span><span class="Bold">PRODUCING <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>. ALCOHOL, OTHER OPIOIDS</span><span class="Bold">AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVEHYPNOTICS)</span><span class="Bold">POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS</span><span class="Bold">OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY</span><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> THAT MIGHT RESULT IN <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</span>   </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_3c6ba89a-babd-4eb4-9958-20a4cc890612"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic.</p>
<p>The chemical name of DILAUDID (hydromorphone hydrochloride) is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The structural formula is:</p>
<div class="Figure"><img alt="Alt text" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4daba60f-af60-4c7e-916e-f2ad7e7532c5&amp;name=4daba60f-af60-4c7e-916e-f2ad7e7532c5-01.jpg"></div>
<p>M.W. 321.8</p>
<p>Each 5 mL (1 teaspoon) of DILAUDID ORAL LIQUID contains 5 mg of hydromorphone hydrochloride. In addition, other ingredients include purified water, methylparaben, propylparaben, sucrose, and glycerin.  DILAUDID ORAL LIQUID may contain traces of sodium metabisulfite.</p>
<p>Color Coded Tablets (for oral administration) contain:</p>
<p>2 mg hydromorphone hydrochloride (orange tablet) and D&amp;C red #30 Lake dye, D&amp;C yellow #10 Lake dye, lactose, and magnesium stearate.  DILAUDID 2 mg TABLET may contain traces of sodium metabisulfite.</p>
<p>4 mg hydromorphone hydrochloride (yellow tablet) and D&amp;C yellow #10 Lake dye, lactose, and magnesium stearate. DILAUDID 4 mg TABLET may contain traces of sodium metabisulfite.</p>
<p>8 mg hydromorphone hydrochloride (white tablet) and lactose anhydrous, and magnesium stearate. DILAUDID 8 mg TABLET may contain traces of sodium metabisulfite.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_052101f8-2587-4ec0-97b3-60105bebc579"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydromorphone hydrochloride is a pure opioid agonist with the principal therapeutic activity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. A significant feature of the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is that it can occur without <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. Opioid analgesics also suppress the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex and may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and electroencephalographic changes. Many of the effects described below are common to this class of mu-opioid agonist analgesics which includes morphine, oxycodone, hydrocodone, codeine and fentanyl. In some instances, data may not exist to distinguish the effects of DILAUDID ORAL LIQUID and DILAUDID TABLETS from those observed with other opioid analgesics. However, in the absence of data to the contrary, it is assumed that DILAUDID ORAL LIQUID and DILAUDID TABLETS would possess all the actions of mu-agonist opioids.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b9e7ef1-281e-4075-b006-6b7333d38e55"></a><a name="section-2.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">The precise mode of analgesic action of opioid analgesics is unknown. However, specific CNS opiate receptors have been identified.  Opioids are believed to express their pharmacological effects by combining with these receptors.</p>
<p>Hydromorphone depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla.</p>
<p>Hydromorphone depresses the respiratory reflex by a direct effect on brain stem respiratory centers. The mechanism of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> also involves a reduction in the responsiveness of the brain stem respiratory centers to increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>.</p>
<p>Hydromorphone causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>. Pinpoint pupils are a common sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> may be seen with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in the setting of DILAUDID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ff24a34-a96c-455e-bdf3-77a591d3ebb7"></a><a name="section-2.2"></a><p></p>
<h2>Gastrointestinal Tract and Other Smooth Muscle </h2>
<p class="First">Gastric, biliary and pancreatic secretions are decreased by opioids such as hydromorphone. Hydromorphone causes a reduction in motility associated with an increase in tone in the gastric antrum and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, and tone may be increased to the point of spasm. The end result is <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Hydromorphone can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa413da8-81c9-460b-8c04-4075e286415d"></a><a name="section-2.3"></a><p></p>
<h2>Cardiovascular System </h2>
<p class="First">Hydromorphone may produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> as a result of either peripheral vasodilation or release of histamine, or both. Other manifestations of histamine release and/or peripheral vasodilation may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_09b040d6-4ae4-4041-a929-3b1282c77195"></a><a name="section-2.4"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">The analgesic activity of DILAUDID (hydromorphone hydrochloride) is due to the parent drug, hydromorphone. Hydromorphone is rapidly absorbed from the gastrointestinal tract after oral administration and undergoes extensive first-pass metabolism. Exposure of hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">0-24</span>) is dose-proportional at a dose range of 2 and 8 mg. In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%).  Bioequivalence between the DILAUDID 8 mg TABLET and an equivalent dose of DILAUDID ORAL LIQUID has been demonstrated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43967b07-171c-42de-b4e1-fedbc173dd07"></a><a name="section-2.4.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">After oral administration of DILAUDID 8 mg liquid or tablets, peak plasma hydromorphone concentrations are generally attained within ½ to 1-hour.</p>
<a name="id_d5e58cf8-82ca-4425-af3e-8f4cdfd6ec92"></a><table border="0" width="0.000">
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="9" valign="top"><span class="Bold"><span class="Emphasis">Mean (%cv) </span></span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Dosage Form </span></span></td>
<td align="left" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">C <span class="Sub">max</span><br> (ng) </span></span></td>
<td align="left" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">T <span class="Sub">max</span><br> (hrs) </span></span></td>
<td align="left" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">AUC <br> (ng*hr/mL) </span></span></td>
<td align="left" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">T ½<br> (hrs) </span></span></td>
</tr>
<tr>
<td align="left" valign="top">8 mg Tablet</td>
<td align="left" valign="top">5.5 (33%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">0.74 (34%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">23.7 (28%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">2.6 (18%)</td>
<td align="left" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">8 mg Oral Liquid</td>
<td align="left" valign="top">5.7 (31%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">0.73 (71%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">24.6 (29%)</td>
<td align="left" valign="top"></td>
<td align="left" valign="top">2.8 (20%)</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f76b91cd-eaaa-4e0c-bae9-84d1ee792079"></a><a name="section-2.4.1.1"></a><p></p>
<h4>Food Effects</h4>
<p class="First">In a study conducted with a single 8 mg dose of hydromorphone(2 mg DILAUDID® IR tablets), food lowered C<span class="Sub">max</span> by 25%, prolonged T<span class="Sub">max</span> by 0.8 hour, and increased AUC by 35%. The effects may not be clinically relevant.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e4c425f-3c29-4465-9871-0e70d58362b2"></a><a name="section-2.4.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">At therapeutic plasma levels, hydromorphone is approximately 8-19% bound to plasma proteins. After an intravenous bolus dose, the steady state of volume distribution [mean (%cv)] is 302.9 (32%) liters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65a186b5-9c0a-4f28-abd4-5ef9376f9b9a"></a><a name="section-2.4.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Hydromorphone is extensively metabolized via glucuronidationin the liver, with greater than 95% of the dose metabolized to hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64eff8ab-c17b-4158-8d60-054643038996"></a><a name="section-2.4.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites. The systemic clearance is approximately 1.96 (20%) liters/minute. The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_9d7ea867-ba8d-4441-badf-56972d645840"></a><a name="section-2.5"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b49f5c3b-1da1-47d2-acd1-49d4213bfbef"></a><a name="section-2.5.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h3>
<p class="First">After oral administration of hydromorphone at a single 4 mg dose (2 mg Dilaudid IR Tablets), mean exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">∞</span>) is increased 4-fold in patients with moderate (Child-Pugh Group B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with subjects with normal hepatic function. Due to increased exposure of hydromorphone, patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be started at a lower dose and closely monitored during dose titration. Pharmacokinetics of hydromorphone in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> patients has not been studied. Further increase in C<span class="Sub">max</span> and AUC of hydromorphone in this group is expected. As such, starting dose should be even more conservative. Use of oral liquid is recommended to adjust the dose (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_195ba01c-39c4-4470-a767-b3c76fbf49f6"></a><a name="section-2.5.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h3>
<p class="First">After oral administration of hydromorphone at a single 4 mg dose (2 mg Dilaudid IR Tablets), exposure to hydromorphone (C<span class="Sub">max</span> and AUC<span class="Sub">0-48</span>) is increased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> by 2-fold in moderate (CLcr = 40 - 60 mL/min) and 3-fold in severe (CLcr &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with normal subjects (CLcr &gt; 80 mL/min). In addition, in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> hydromorphone appeared to be more slowly eliminated with longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr). Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be started on a lower dose. Starting doses for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be even lower. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored during dose titration. Use of oral liquid is recommended to adjust the dose (see <span class="Bold">DOSAGE AND</span><span class="Bold">ADMINISTRATION</span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_4c874fec-1c89-40cc-b669-8c8b79e8e4f1"></a><a name="section-2.5.3"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">Pharmacokinetics of hydromorphone have not been evaluatedin children. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_50fe528a-a870-4085-8104-b175dbe50a87"></a><a name="section-2.5.4"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Age has no effect on the pharmacokinetics of hydromorphone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24afc619-1b0a-45b6-9121-2cc9cf51b4a8"></a><a name="section-2.5.5"></a><p></p>
<h3>Gender</h3>
<p class="First">Gender has little effect on the pharmacokinetics of hydromorphone.Females appear to have higher C<span class="Sub">max</span> (25%) than males with comparable AUC<span class="Sub">0-24</span> values. The difference observed in C<span class="Sub">max</span> may not be clinically relevant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_195f994c-d70c-4c64-bf57-b23dd8c9d1ad"></a><a name="section-2.5.6"></a><p></p>
<h3>Pregnancy and Nursing Mothers</h3>
<p class="First">Hydromorphone crosses the placenta. Hydromorphone is also found in low levels in breast milk, and may cause respiratory compromise in newborns when administered during labor or delivery.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_39137b28-8cdc-4ec6-a9c7-500b0c19c4a3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesic effects</span> of single doses of DILAUDID ORAL LIQUIDadministered to patients with post-surgical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> have been studied in double-blind controlled trials. In one study, both 5 mg and 10 mg of DILAUDID ORAL LIQUID provided significantly more <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> than placebo. In another trial, 5 mg and 10 mg of DILAUDID ORAL LIQUID were compared to 30 mg and 60 mg of morphine sulfate oral liquid. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief provided by 5 mg and 10 mg DILAUDID ORAL LIQUID was comparable to 30 mg and 60 mg oral morphine sulfate, respectively.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f4fb4721-c507-435f-b285-6c22a6e03879"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS are indicated for the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients where an opioid analgesic is appropriate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_69829857-366e-47c3-8cd8-5d03216575fa"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS are contraindicated in: patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydromorphone, patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the absence of resuscitative equipment, and in patients with status asthmaticus. DILAUDID ORAL LIQUID and DILAUDID TABLETS are also contraindicated for use in obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_77a17ca6-ff1d-437a-9576-f2bfc7a82afc"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba2c2c81-51cc-43bc-9f5d-edee072a94c9"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief hazard of DILAUDID ORAL LIQUID and DILAUDID TABLETS. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is more likely to occur in the elderly, in the debilitated, and in those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span> when even moderate therapeutic doses may dangerously decrease pulmonary ventilation.</p>
<p>DILAUDID ORAL LIQUID and DILAUDID TABLETS should be used with extreme caution in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, patients having a substantially decreased respiratory reserve, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or in patients with preexisting <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients even usual therapeutic doses of opioid analgesics may decrease respiratory drive while simultaneously increasing airway resistance to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p><span class="Bold">DILAUDID ORAL LIQUID and DILAUDID TABLETS contain</span><span class="Bold">hydromorphone, which is a potent Schedule II controlled opioid</span><span class="Bold">agonist. Schedule II opioid agonists, including morphine,</span><span class="Bold">oxymorphone, oxycodone, fentanyl, and methadone, have the highest</span><span class="Bold">potential for abuse and risk of producing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</span><span class="Bold">Alcohol, other opioids and central nervous system depressants</span><span class="Bold">(sedative-hypnotics) potentiate the respiratory depressant effects of</span><span class="Bold">hydromorphone, increasing the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> that</span><span class="Bold">might result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e1560d9c-4ef7-4fc1-b20c-add99e5c60fc"></a><a name="section-6.2"></a><p></p>
<h2>Misuse, Abuse, and Diversion of Opioids</h2>
<p class="First">Hydromorphone is an opioid agonist of the morphine-type.  Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.</p>
<p>DILAUDID can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing DILAUDID in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.</p>
<p>Prescribers should monitor all patients receiving opioids for signs of abuse, misuse, and addiction. Furthermore, patients should be assessed for their potential for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> prior to being prescribed opioid therapy. Persons at increased risk for <span class="product-label-link" type="condition" conceptid="436954" conceptname="Drug abuse">opioid abuse</span> include those with a personal or family history of <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> (including drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>) or mental illness (e.g., <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>). Opioids may still be appropriate for use in these patients, however, they will require intensive monitoring for signs of abuse.</p>
<p>DILAUDID has been reported as being abused by crushing, chewing, snorting, or injecting the dissolved product. These practices pose a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <span class="Bold">WARNINGS </span>and <span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span>).</p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p>Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a56c1d8-9d34-4da1-b468-ac80f31e6fb7"></a><a name="section-6.3"></a><p></p>
<h2>Interactions with Alcohol and Drugs of Abuse </h2>
<p class="First">Hydromorphone may be expected to have additive effects whenused in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9aab392d-d10a-4ca9-aeca-a97a38ceaca3"></a><a name="section-6.4"></a><p></p>
<h2>Neonatal Withdrawal Syndrome</h2>
<p class="First">Infants born to mothers physically dependent on DILAUDID will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms (see <span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdcd4ed3-32b8-4776-b3cc-965985b58d39"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> </h2>
<p class="First">The respiratory depressant effects of DILAUDID ORAL LIQUID and DILAUDID TABLETS with <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or preexisting increase in intracranial pressure. Opioid analgesics including DILAUDID ORAL LIQUID and DILAUDID TABLETS (hydromorphone hydrochloride) may produce effects on pupillary response and consciousness which can obscure the clinical course and neurologic signs of further increase in intracranial pressure in patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cf8be8bf-2940-4cba-87b8-5699a16d1338"></a><a name="section-6.6"></a><p></p>
<h2>Hypotensive Effect</h2>
<p class="First">Opioid analgesics, including DILAUDID ORAL LIQUID and DILAUDID TABLETS, may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume, or a concurrent administration of drugs such as phenothiazines or general anesthetics (see <span class="Bold">PRECAUTIONS - Drug Interactions</span>). Therefore, DILAUDID ORAL LIQUID and DILAUDID TABLETS should be administered with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_253753fa-8388-4d41-bec5-1b1077ad2a77"></a><a name="section-6.7"></a><p></p>
<h2>Sulfites</h2>
<p class="First">Contains sodium metabisulfite, a sulfite that may cause allergictypereactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_16220a29-c3ed-4015-af57-05e7218d741b"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2008153-0290-4275-bb67-79e6eb0a9c04"></a><a name="section-7.1"></a><p></p>
<h2>Special Risk Patients</h2>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS should be given with caution and the initial dose should be reduced in the elderly or debilitated and those with severe impairment of hepatic, pulmonary or renal functions; <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>; adrenocortical insufficiency (e.g., Addison’s Disease); <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; toxic psychoses; <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>; gall bladder disease; acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>; <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>; kyphoscoliosis or following gastrointestinal surgery.  </p>
<p>The administration of opioid analgesics including DILAUDID ORAL LIQUID and DILAUDID TABLETS may obscure the diagnoses or clinical course in patients with acute abdominal conditions and may aggravate preexisting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>.</p>
<p>Reports of mild to severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span> have been reported in severely compromised patients, administered high doses of parenteral hydromorphone, for cancer and severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  Opioid administration at very high doses is associated with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span> in a variety of diseases where <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control is the primary focus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31b400c2-e0df-40aa-9676-3c5f02d0245f"></a><a name="section-7.2"></a><p></p>
<h2>Use in Drug and Alcohol Dependent Patients </h2>
<p class="First">DILAUDID should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and other drug dependencies due to the increased frequency of opioid tolerance, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and the risk of addiction observed in these patient populations. Abuse of DILAUDID in combination with other CNS depressant drugs can result in serious risk to the patient.</p>
<p>Hydromorphone is an opioid with no approved use in the management of addictive disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e761d0f7-9965-456e-b5a4-14655232f5f5"></a><a name="section-7.3"></a><p></p>
<h2>Use in Ambulatory Patients</h2>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS may impairmental and/or physical ability required for the performance of potentially hazardous tasks (e.g. driving, operating machinery).  Patients should be cautioned accordingly. DILAUDID may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a19fadd-cd31-47fd-8c9b-c67bea421f8b"></a><a name="section-7.4"></a><p></p>
<h2>Use in <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Opioid analgesics, including DILAUDID ORAL LIQUID andDILAUDID TABLETS, should also be used with caution in patients about to undergo surgery of the biliary tract since it may cause spasm of the sphincter of Oddi.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_9a6744a4-d3d4-4392-8870-1184b04b4000"></a><a name="section-7.5"></a><p></p>
<h2>Tolerance and Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy.</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p>In general, opioids used regularly should not be abruptly discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d136681d-933f-4166-a07d-f77838f5e837"></a><a name="section-7.6"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<p class="First">Patients receiving DILAUDID (hydromorphone hydrochloride) ORAL LIQUID or DILAUDID TABLETS or their caregivers should be given the following information by the physician, nurse, or pharmacist:</p>
<p>1. Patients should be aware that DILAUDID tablets contain hydromorphone, which is a morphine-like substance and which could cause severe adverse effects including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if not taken according to the prescriber’s directions.</p>
<p>2. Patients should be advised to report <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.</p>
<p>3. Patients should be advised not to adjust the dose of DILAUDID without consulting the prescribing professional.</p>
<p>4. Patients should be advised that DILAUDID may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).</p>
<p>5. Patients should not combine DILAUDID with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>6. Women of childbearing potential who become, or are planning to become pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.</p>
<p>7. Patients should be advised that DILAUDID is a potential drug of abuse. They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it was prescribed. </p>
<p>8. Patients should be advised that if they have been receiving treatment with DILAUDID for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the DILAUDID dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.</p>
<p>9. Patients should be instructed to keep DILAUDID in a secure place out of the reach of children. When DILAUDID is no longer needed, the unused tablets should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> down the toilet.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5ebc13d7-0b40-4edf-aee0-846fa83e70aa"></a><a name="section-7.7"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b414947c-8943-4851-b40d-7c2c3aed7cc1"></a><a name="section-7.7.1"></a><p></p>
<h3>Drug Interactions with Other CNS Depressants </h3>
<p class="First">The concomitant use of other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers and alcohol may produce additive depressant effects. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and profound sedation or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur. When such combined therapy is contemplated, the dose of one or both agents should be reduced. DILAUDID should not be taken with alcohol. Opioid analgesics, including DILAUDID ORAL LIQUID and DILAUDID TABLETS, may enhance the action of neuromuscular blocking agents and produce an excessive degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25dc0476-2df6-462f-ab25-f3d702ee1633"></a><a name="section-7.7.2"></a><p></p>
<h3>Interactions with Mixed Agonist/Antagonist Opioid Analgesics</h3>
<p class="First">Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine,butorphanol, and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with apure opioid agonist analgesic such as hydromorphone. In this situation, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of hydromorphone and/or may precipitate withdrawal symptoms in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4f9d9903-00da-46b4-8b17-e3da7d5c37cf"></a><a name="section-7.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been conducted in animals. Hydromorphone was not mutagenic in the in vitro Ames reverse mutation assay or the human lymphocyte chromosome aberration assay. Hydromorphone was not clastogenic in the in vivo mouse micronucleus assay.</p>
<p>No effects on fertility, reproductive performance, or reproductive organ morphology were observed in male or female rats given oral doses up to 7 mg/kg/day, which is equivalent to the human dose of 2.5-10 mg every 3 to 6 hours for oral liquid, and 3-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_1b0aff12-7684-4201-ad41-5c05442ffc3c"></a><a name="section-7.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74099217-b3f7-4b01-a98a-4ba32bb98844"></a><a name="section-7.9.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">No effects on <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or embryotoxicity were observed in female rats given oral doses up to 7 mg/kg/day, which is approximately equivalent to the human dose of 2.5-10 mg every 3 to 6 hours for oral liquid, and 3-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. <span class="Bold">Hydromorphone </span>produced skull malformations (<span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> and cranioschisis) in Syrian hamsters given oral doses up to 20 mg/kg during the peak of organogenesis (gestation days 8-9). The skull malformations were observed at doses approximately 2-fold higher the human dose of 2.5-10 mg every 3 to 6 hours for oral liquid, and 7-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. There are no adequate and well-controlled studies of DILAUDID in pregnant women.</p>
<p>Hydromorphone crosses the placenta, resulting in fetal exposure. DILAUDID ORAL LIQUID and DILAUDID TABLETS should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus (see <span class="Bold">Labor and Delivery </span>and <span class="Bold">DRUG ABUSE</span><span class="Bold">AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_747d5e1d-a921-45c7-95a2-3ec0243970ba"></a><a name="section-7.9.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Approaches to the treatment of this syndrome have included supportive care and, when indicated, drugs such as paregoric or phenobarbital.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_8d87076d-2808-4278-95ef-c8f45d227ea6"></a><a name="section-7.10"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS are contraindicated in Labor and Delivery (see <span class="Bold">CONTRAINDICATIONS</span>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_30d1c55f-70fe-44aa-b03e-4b336d0198f5"></a><a name="section-7.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Low levels of opioid analgesics have been detected in human milk. As a general rule, nursing should not be undertaken while a patient is receiving DILAUDID ORAL LIQUID and DILAUDID TABLETS since it, and other drugs in this class, may be excreted in the milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_85a52aa8-2877-4c83-843d-fd588186622e"></a><a name="section-7.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_aeae5523-3440-48c8-824a-e94f571a1a3b"></a><a name="section-7.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DILAUDID did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see <span class="Bold">INDIVIDUALIZATION OF DOSAGES </span>and <span class="Bold">PRECAUTIONS</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_2f87e791-8c72-405d-9ef3-56689db2e41c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The major hazards of DILAUDID ORAL LIQUID and DILAUDID TABLETS include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. To a lesser degree, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred.</p>
<p>The most frequently observed adverse effects are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a03d82e-81c7-4556-b384-318be14d022b"></a><a name="section-8.1"></a><p></p>
<h2>Less Frequently Observed Adverse Reactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82509dd3-bf65-4b1a-91b5-f2bcc7e7c99f"></a><a name="section-8.1.1"></a><p></p>
<h3>General and CNS</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, uncoordinated musclemovements, alterations of mood (<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">floating feelings</span>, dreams), <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, muscle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> and <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, transient <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3405da04-049d-49dc-bd45-5fa4bc91639c"></a><a name="section-8.1.2"></a><p></p>
<h3>Cardiovascular</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the face, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, faintness, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6735abc3-2c5e-40d8-aca6-6d3b3df09509"></a><a name="section-8.1.3"></a><p></p>
<h3>Respiratory </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bdd3308-3bca-4fb1-b7d8-8472781c7744"></a><a name="section-8.1.4"></a><p></p>
<h3>Gastrointestinal</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, biliary tract spasm, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_255d33ec-377e-4760-8d0e-298a98f9df36"></a><a name="section-8.1.5"></a><p></p>
<h3>Genitourinary</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> or <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">hesitancy</span>, antidiuretic effects</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e50cf4ae-7320-4b75-a717-f8a51717b327"></a><a name="section-8.1.6"></a><p></p>
<h3>Dermatologic</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, other <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_84c14de7-9cd0-4d5b-9443-94c2c807ab20"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious overdosage with DILAUDID ORAL LIQUID and DILAUDID TABLETS is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In serious overdosage, particularly following intravenous injection, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
<p>In the treatment of overdosage, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. A potentially serious oral ingestion, if recent, should be managed with gut decontamination. In <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patients with a secure airway, instill activated charcoal (30-100 g in adults, 1-2 g/kg in infants) via a nasogastric tube. A saline cathartic or sorbitol may be added to the first dose of activated charcoal.</p>
<p>Supportive measures (including oxygen, vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>The opioid antagonist, naloxone, is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage, or unusual sensitivity to DILAUDID ORAL LIQUID and DILAUDID TABLETS. Therefore, an appropriate dose of this antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Naloxone should not be administered in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Naloxone should be administered cautiously to persons who are known, or suspected to be physically dependent on DILAUDID ORAL LIQUID and DILAUDID TABLETS. In such cases, an abrupt or complete reversal of narcotic effects may precipitate an acute withdrawal syndrome. Since the duration of action of DILAUDID ORAL LIQUID and DILAUDID TABLETS may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. Apply other supportive measures when indicated.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c8bd43ea-c8fe-4bcf-aaf2-77515f10096b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_537f11a0-39d2-4628-8251-739c2a6a2445"></a><a name="section-10.1"></a><p></p>
<h2>Dilaudid Oral Liquid</h2>
<p class="First">The usual adult oral dosage of DILAUDID ORAL LIQUID is one-half (2.5 mL) to two teaspoonfuls (10 mL) (2.5 mg - 10 mg) every 3 to 6 hours as directed by the clinical situation. Oral dosages higher than the usual dosages may be required in some patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7583ea9d-22d8-4b84-bf52-e22daf47e2c5"></a><a name="section-10.2"></a><p></p>
<h2>Dilaudid Tablets</h2>
<p class="First">The usual starting dose for DILAUDID tablets is 2 mg to 4 mg, orally, every 4 to 6 hours. Appropriate use of the DILAUDID TABLETS must be decided by careful evaluation of each clinical situation.</p>
<p>A gradual increase in dose may be required if <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is inadequate, as tolerance develops, or if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> severity increases. The first sign of tolerance is usually a reduced duration of effect.  Patients with hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be started on a lower starting dose (See <span class="Bold">CLINICAL PHARMACOLOGY - Pharmacokinetics</span><span class="Bold">and Metabolism</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d467db4-b440-4897-aa3f-0c2041d94a59"></a><a name="section-11"></a><p></p>
<h1>INDIVIDUALIZATION OF DOSAGE</h1>
<p class="First">The dosage of opioid analgesics like hydromorphone hydrochloride should be individualized for any given patient, since adverse events can occur at doses that may not provide complete freedom from <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Safe and effective administration of opioid analgesics to patients with acute or <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> depends upon a comprehensive assessment of the patient. The nature of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (severity, frequency, etiology, and pathophysiology) as well as the concurrent medical status of the patient will affect selection of the starting dosage.</p>
<p>In non-opioid-tolerant patients, therapy with hydromorphone is typically initiated at an oral dose of 2-4 mg every four hours, but elderly patients may require lower doses (see <span class="Bold">PRECAUTIONS - Geriatric Use</span>).</p>
<p>In patients receiving opioids, both the dose and duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> will vary substantially depending on the patient's opioid tolerance. The dose should be selected and adjusted so that at least 3-4 hours of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief may be achieved. In patients taking opioid analgesics, the starting dose of DILAUDID should be based on prior opioid usage. This should be done by converting the total daily usage of the previous opioid to an equivalent total daily dosage of oral DILAUDID using an equianalgesic table (see below). For opioids not in the table, first estimate the equivalent total daily usage of oral morphine, then use the table to find the equivalent total daily dosage of DILAUDID.</p>
<p>Once the total daily dosage of DILAUDID has been estimated, it should be divided into the desired number of doses. Since there is individual variation in response to different opioid drugs, only 1/2 to 2/3 of the estimated dose of DILAUDID calculated from equivalence tables should be given for the first few doses, then increased as needed according to the patient's response.</p>
<p>Since the pharmacokinetics of hydromorphone are affected in hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with a consequent increase in exposure, patients with hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be started on a lower starting dose (See <span class="Bold">CLINICAL PHARMACOLOGY - Pharmacokinetics</span></p>
<p><span class="Bold">and Metabolism</span>).</p>
<p>In <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span>, doses should be administered around-theclock.  A supplemental dose of 5-15% of the total daily usage may be administered every two hours on an “as-needed? basis.</p>
<p>Periodic reassessment after the initial dosing is always required. If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management is not satisfactory and in the absence of significant opioid-induced adverse events, the hydromorphone dose may be increased gradually. If excessive opioid side effects are observed early in the dosing interval, the hydromorphone dose should be reduced. If this results in breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the end of the dosing interval, the dosing interval may need to be shortened. Dose titration should be guided more by the need for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> than the absolute dose of opioid employed.</p>
<a name="id_2eac08df-530f-45a3-a8a3-682fe73d91aa"></a><table border="0" width="0.000">
<caption><span>OPIOID ANALGESIC EQUIVALENTS WITH APPROXIMATELY EQUIANALGESIC POTENCY*</span></caption>
<col>
<col>
<col>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top">* Dosages, and ranges of dosages represented, are a compilation of estimated equipotent dosages from published references comparing opioid analgesics in cancer and severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Nonproprietary <br> (Trade) Name </span></span></td>
<td class="Toprule" align="left" valign="top"><span class="Bold"><span class="Emphasis">IM or SC <br> Dose </span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">ORAL <br> Dose </span></span></td>
</tr>
<tr>
<td align="left" valign="top">Morphine sulfate</td>
<td align="left" valign="top">10 mg</td>
<td align="left" valign="top">40-60 mg</td>
</tr>
<tr>
<td align="left" valign="top">Hydromorphone HCl<br> (DILAUDID) </td>
<td align="left" valign="top">
<br> 1.3-2 mg </td>
<td align="left" valign="top">
<br> 6.5-7.5 mg </td>
</tr>
<tr>
<td align="left" valign="top">Oxymorphone HCl<br> (Numorphan) </td>
<td align="left" valign="top">
<br> 1-1.1 mg </td>
<td align="left" valign="top">
<br> 6.6 mg </td>
</tr>
<tr>
<td align="left" valign="top">Levorphanol tartrate<br> (Levo-Dromoran) </td>
<td align="left" valign="top">
<br> 2-2.3 mg </td>
<td align="left" valign="top">
<br> 4 mg </td>
</tr>
<tr>
<td align="left" valign="top">Meperidine, pethidine HCl<br> (Demerol) </td>
<td align="left" valign="top">
<br> 75-100 mg </td>
<td align="left" valign="top">
<br> 300-400 mg </td>
</tr>
<tr class="Last">
<td align="left" valign="top">Methadone HCl<br> (Dolophine) </td>
<td align="left" valign="top">
<br> 10 mg </td>
<td align="left" valign="top">
<br> 10-20 mg </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_3d378942-4cb7-4021-a354-1484a493fb92"></a><a name="section-12"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"><span class="Bold">DILAUDID ORAL LIQUID and DILAUDID TABLETS contain</span><span class="Bold">hydromorphone, a Schedule II controlled opioid agonist. Schedule II</span><span class="Bold">opioid substances which include morphine, oxycodone, oxymorphone,</span><span class="Bold">fentanyl, and methadone have the highest potential for abuse and risk</span><span class="Bold">of fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Hydromorphone can be abused and is subject to</span><span class="Bold">criminal diversion. </span></p>
<p><span class="Bold">Opioid analgesics may cause psychological and physical </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> results in withdrawal symptoms </span><span class="Bold">in patients who abruptly discontinue the drug. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> </span><span class="Bold">usually does not occur to a clinically significant degree until after </span><span class="Bold">several weeks of continued opioid usage, but it may occur after as </span><span class="Bold">little as a week of opioid use. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance </span><span class="Bold">are separate and distinct from abuse and addiction.</span></p>
<p>Addiction is a chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.</p>
<p>“Drug seeking? behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss? of prescriptions, tampering with, forging or counterfeiting prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s).  “Doctor shopping? to obtain additional prescriptions is common among drug abusers, people suffering from untreated addiction and criminals seeking drugs to sell.</p>
<p>Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for nonmedical purposes, often in combination with other psychoactive substances. Since DILAUDID ORAL LIQUID and DILAUDID TABLETS may be diverted for non-medical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised. </p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p>DILAUDID ORAL LIQUID and DILAUDID TABLETS are intended for oral use only. Misuse or abuse of DILAUDID ORAL LIQUID and DILAUDID TABLETS pose a risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This risk is increased with concurrent abuse of alcohol and other CNS depressants. Parenteral drug abuse can potentially result in local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, pulmonary <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">granulomas</span>, and increased risk of <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and valvular <span class="product-label-link" type="condition" conceptid="4016543" conceptname="Injury to heart and lung">heart injury</span>. In addition, parenteral abuse is commonly associated with transmission of infectious diseases such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and HIV.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48705a2e-3d7b-4dd7-8c77-21b8f90169dc"></a><a name="section-13"></a><p></p>
<h1>SAFETY AND HANDLING INSTRUCTIONS</h1>
<p class="First">DILAUDID ORAL LIQUID and DILAUDID TABLETS pose little risk of direct exposure to health care personnel and should be handled and disposed of prudently in accordance with hospital or institutional policy. Significant absorption from dermal exposure is unlikely; accidental dermal exposure to DILAUDID ORAL LIQUID should be treated by removal of any contaminated clothing and rinsing the affected area with cool water.  Patients and their families should be instructed to flush any DILAUDID ORAL LIQUID and DILAUDID TABLETS that are no longer needed.</p>
<p>Access to abuseable drugs such as DILAUDID ORAL LIQUID and DILAUDID TABLETS presents an occupational hazard for addiction in the health care industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect health care workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by health care providers.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a605ced8-31d6-4297-be0d-4c601b881dae"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DILAUDID ORAL LIQUID is a clear, sweet, slightly viscous liquid.  It is available in: Bottles of 1 pint (473 mL) - NDC# 59011-451-01</p>
<p>DILAUDID 2 mg TABLETS are orange, debossed with a P on one side and the number 2 on the opposite side. They are available in: Bottles of 100 - NDC# 59011-452-10</p>
<p>Unit Dose Packages of 100 (4x25) - NDC# 59011-452-01.</p>
<p>DILAUDID 4 mg TABLETS are yellow, debossed with a P on one side and the number 4 on the opposite side. They are available in: Bottles of 100 - NDC# 59011-454-10</p>
<p>Unit Dose Packages of 100 (4x25) - NDC# 59011-454-01.</p>
<p>Bottles of 500 - NDC# 59011-454-05 </p>
<p>DILAUDID 8 mg TABLETS are white and triangular shaped, debossed with a double P on one side and bisected and debossed with the number 8 on the opposite side. They are available in: Bottles of 100 - NDC# 59011-458-10</p>
<p>Healthcare professionals can telephone Purdue Pharma’s Medical Services Department (1-888-726-7535) for information on this product.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_97428fb1-31ae-4bbf-a1ca-deb4fcb0e6d7"></a><a name="section-15"></a><p></p>
<h1>Storage</h1>
<p class="First">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature]. Protect from light.</p>
<p>A schedule CS-II Narcotic. DEA Order Form is Required.</p>
<p>Manufactured for Purdue Pharma L.P. Stamford, CT 06901-3431 By Halo Pharmaceuticals, Inc. Whippany, NJ 07981</p>
<p>Revised: March 5, 2009</p>
<p>302064-0A</p>
<p>Cardinal Health</p>
<p>Zanesville OH 43701 </p>
<p>IR2270310</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_069cb84d-d104-41c1-a939-dcaa60e052b2"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL-4 mg</h1>
<p class="First">NDC: 59011-454-10  (PURDUE)</p>
<p>100 Tablets</p>
<p>CII</p>
<p>Dilaudid</p>
<p>(hydromorphone HCl)</p>
<p>4 mg</p>
<p>Each tablet contains: 4 mg hydromorphone HCl</p>
<p>Purdue </p>
<p>Rx ONLY</p>
<p>WARNING: Keep out of reach of children.</p>
<div class="Figure"><img alt="Dilaudid label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4daba60f-af60-4c7e-916e-f2ad7e7532c5&amp;name=4daba60f-af60-4c7e-916e-f2ad7e7532c5-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DILAUDID 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-1610(NDC:59011-454)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydromorphone hydrochloride</strong> (hydromorphone) </td>
<td class="formItem">hydromorphone hydrochloride</td>
<td class="formItem">4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">P;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-1610-1</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019892</td>
<td class="formItem">01/01/1926</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Purdue Pharma LP (932323652)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4daba60f-af60-4c7e-916e-f2ad7e7532c5</div>
<div>Set id: 4daba60f-af60-4c7e-916e-f2ad7e7532c5</div>
<div>Version: 1</div>
<div>Effective Time: 20110104</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
